Accéder au contenu
Merck
Toutes les photos(1)

Documents

RAB0849

Sigma-Aldrich

Mouse Tnfsf10 / Tumor Necrosis Factor Ligand Superfamily Member 10 ELISA Kit

for serum, plasma and cell culture supernatants

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Code UNSPSC :
41116158
Nomenclature NACRES :
NA.32

Espèces réactives

mouse

Conditionnement

kit of 96 wells (12 strips x 8 wells)

Technique(s)

ELISA: suitable

Entrée

sample type plasma
sample type serum
sample type cell culture supernatant(s)

assay range

inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 2 pg/mL
standard curve range: 2.46-600 pg/mL

Méthode de détection

colorimetric

Conditions d'expédition

wet ice

Température de stockage

−20°C

Informations sur le gène

mouse ... Tnfsf10(22035)

Description générale

The antibody pair provided in this kit recognizes mouse TRAIL/TNFSF10.

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Actions biochimiques/physiologiques

Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) activates the extrinsic apoptotic pathway by binding death receptors (DR)-4 and 5. In addition to DR 4 and 5, TRAIL activates several other receptors such as decoy receptor (DcR)1, DcR2 and a soluble receptor called osteoprotegerin. TRAIL plays a vital role in the inhibition of autoimmune inflammation and cell cycle progression. TRAIL selectively kills tumor cells without damaging normal tissues and therefore, it might act as a tumor-selective anticancer agent. TRAIL-induced apoptosis is involved in various cellular processes including activation-induced cell death, homeostasis, intrathymic negative selection, autoimmunity suppression, and immune surveillance. Repeated dosage of recombinant soluble TRAIL triggers apoptosis, inhibits tumor progression, and increases viability of mice suffering from cancer.

Autres remarques

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Composants de kit également disponibles séparément

Réf. du produit
Description
FDS
  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)FDS
  • RABSTOP3ELISA Stop Solution (Item I)FDS
  • RABELADAELISA 1X Assay/Sample Diluent Buffer A (Item D1)FDS
  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)FDS
  • RABWASH420X Wash Buffer (Item B)FDS

Pictogrammes

Corrosion
GHS05

Mention d'avertissement

Warning

Mentions de danger

H290

Conseils de prudence

P234 - P390

Classification des risques

Met. Corr. 1

Code de la classe de stockage

8A - Combustible corrosive hazardous materials

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice
Shi J
Cancer Research, 65 (2005)
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induced mitochondrial pathway to apoptosis and caspase activation is potentiated by phospholipid scramblase-3
Ndebele K
Apoptosis, 13(7) (2008)
Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetus
Stenqvist AC
Journal of Immunology, 191, 5515-5523 (2013)
Lin Li et al.
Acta biochimica et biophysica Sinica, 46(6), 471-476 (2014-04-18)
The apoptotic ligand TNF-related apoptosis-inducing ligand (TRAIL) is believed to be a promising candidate for cancer gene therapy, yet gene therapy strategies to tackle this disease systemically are often impaired by inefficient delivery of the vector to the tumor tissue.
A Ray et al.
Leukemia, 28(8), 1716-1724 (2014-01-31)
Our prior study in multiple myeloma (MM) patients showed increased numbers of plasmacytoid dendritic cells (pDCs) in the bone marrow (BM), which both contribute to immune dysfunction as well as promote tumor cell growth, survival and drug resistance. Here we

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique